Literature DB >> 26303885

Autonomic Dysregulation as a Therapeutic Target for Acute HF.

Anju Bhardwaj1, Mark E Dunlap.   

Abstract

OPINION STATEMENT: Despite major advances that have led to effective therapeutic modalities for the treatment of heart failure (HF), this syndrome has continued to be a staggering health problem associated with significant mortality and morbidity. The increasing number of hospital admissions and readmissions related to acute HF continues to pose a fiscal challenge leading to constant interest in development of novel approaches. These point to multiple areas of unmet needs especially in acute HF, thus, necessitating further efforts to develop novel strategies for prevention and treatment of acute HF. One area of continuing focus is targeting the role of autonomic imbalance associated with the development of HF. Autonomic dysregulation, manifested by increased sympathetic drive and reduced parasympathetic activity, has been recognized as a mediator of increased mortality and morbidity in HF and myocardial infarction. Furthermore, vagal withdrawal has been shown to precede acute decompensation, though whether this represents cause or effect is unknown. This review discusses the potential role of autonomic dysregulation as a therapeutic modality for patients with acute decompensated HF.

Entities:  

Year:  2015        PMID: 26303885     DOI: 10.1007/s11936-015-0403-0

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  73 in total

1.  Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction.

Authors:  Daniela Fraccarollo; Julian D Widder; Paolo Galuppo; Thomas Thum; Dimitrios Tsikas; Michael Hoffmann; Hartmut Ruetten; Georg Ertl; Johann Bauersachs
Journal:  Circulation       Date:  2008-08-04       Impact factor: 29.690

2.  Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure.

Authors:  G W Moe; A Albernaz; G O Naik; M Kirchengast; D J Stewart
Journal:  Cardiovasc Res       Date:  1998-09       Impact factor: 10.787

3.  Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF.

Authors:  Paul J Hauptman; Peter J Schwartz; Michael R Gold; Martin Borggrefe; Dirk J Van Veldhuisen; Randall C Starling; Douglas L Mann
Journal:  Am Heart J       Date:  2012-06       Impact factor: 4.749

4.  Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure.

Authors:  B Casadei; J Conway; C Forfar; P Sleight
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

5.  The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.

Authors:  Simon Thackray; Joanne Easthaugh; Nick Freemantle; John G F Cleland
Journal:  Eur J Heart Fail       Date:  2002-08       Impact factor: 15.534

6.  Adverse consequences of high sympathetic nervous activity in the failing human heart.

Authors:  D M Kaye; J Lefkovits; G L Jennings; P Bergin; A Broughton; M D Esler
Journal:  J Am Coll Cardiol       Date:  1995-11-01       Impact factor: 24.094

7.  Acute effect of endothelin AB antagonist on sympathetic outflow in conscious rats with heart failure.

Authors:  Yasuko Tsuchiyama; Ken Kasamatsu; Takuzo Hano; Ichiro Nishio
Journal:  Circ J       Date:  2002-09       Impact factor: 2.993

8.  Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure.

Authors:  A S Androne; K Hryniewicz; R Goldsmith; A Arwady; S D Katz
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

9.  Exercise training normalizes the blunted central component of the baroreflex in rats with heart failure: role of the PVN.

Authors:  Kaushik P Patel; Helio C Salgado; Xuefei Liu; Hong Zheng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-17       Impact factor: 4.733

10.  Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program.

Authors:  Gregg C Fonarow; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Jie Lena Sun; Clyde W Yancy; James B Young
Journal:  J Am Coll Cardiol       Date:  2008-07-15       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.